Leukotriene receptor antagonists in the treatment of asthma: implications for eosinophilic inflammation.
Recent advances in the treatment and management of asthma have suggested that leukotriene (LT) receptor antagonists may be very beneficial as a second generation therapy with steroid-sparing properties and negligible side effects. These agents have shown interesting effects on peripheral blood and sputum eosinophils. A major contributor to the damage in the airway of asthmatic patients is the eosinophil, which, upon activation, releases a battery of granule-associated cytotoxic, cationic proteins, including the major basic protein and eosinophil peroxidase, and membrane-derived de novo-synthesized bioactive lipid mediators, including LTC4, LTD4 and LTE4, as well as PAF (please spell out). These products have deleterious effects on the airway tissue including mucosal and smooth muscle layers. Accumulating evidence suggests that these agents may also influence the accumulation and maintenance of eosinophilic responses at the site of inflammation. This article reviews the possible anti-inflammatory mode of action of these therapies. It also discusses where there may be a gap in the knowledge regarding the potential direct and indirect effects of LT modifiers on eosinophil function and recruitment.
Moqbel
R
R
University of Alberta, Edmonton, Canada. redwan.moqbel@ualberta.ca
D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D004804:Eosinophils / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D020024:Leukotriene Antagonists / Q000627:therapeutic use*
D020024:Leukotriene Antagonists